Tag: IPO
-
Cancer T-Cell Start-Up Gains $150 Million in IPO
A three year-old company developing treatments for cancer with engineered T-cells from the immune system raised $150 million in its initial public offering of common stock.
-
Multi-Drug Resistance Antibiotic Developer to Issue IPO
A three year-old company making new antibiotics to treat infections resistant to earlier antibiotics plans to raise some $75 million in its initial public stock offering.
-
Cancer Gene Therapy Company Raises $85M in IPO
A developer of cancer immunotherapies that transfer gene treatments into patients with brain tumors is raising $85 million in its initial public stock offering.
-
Medical Robotics Company Crowdfunding IPO
A medical robotics company spun-off from labs at MIT is issuing its initial public stock offering through equity crowdfunding, aiming to raise $15 million.
-
Immunotherapy Biotech Raises $102 Million in IPO
A biotechnology company developing treatments for solid tumors, harnessing the body’s immune system, for cancer patients most likely to respond is raising $102 million in its initial public stock offering.
-
Biopharm Company Raising $40 Million in IPO
Omeros Corporation, a biopharmaceutical company developing drugs that prevent inflammation in surgeries, is raising $40 million in its initial public stock offering.
-
Immunotherapy Company Raises $70 Million in IPO
Selecta Biosciences, a biotechnology company developing treatments harnessing the immune system, is raising $70 million in its initial public offering.
-
Genome-Editing Company Raises $108 Million in IPO
6 May 2016. Intellia Therapeutics, a developer of therapies based on genome editing, issued its initial public stock offering, raising $108 million. The Cambridge, Massachusetts enterprise, less than 2 years old, issued 6 million shares priced at $18.00. At the 4:00 pm ET closing bell today, company shares trading on the NASDAQ exchange as NTLA…
-
Cancer Diagnostics Company Raises $12.3M in IPO
18 March 2016. VolitionRx, a developer of blood tests that screen for cancer and other disorders, is raising some $12.3 million in its initial public stock offering. The Namur, Belgium company, listed on the New York Stock Exchange under the symbol VNRX, issued about 3.8 million shares of common stock priced at $3.25. VolitionRx designs…
-
Genome-Editing Company Raises $94 Million in IPO
3 February 2016. Editas Medicine, developer of treatments for disease that harness editing of the human genome, is raising $94.4 million in its initial public stock offering. The company, trading on the Nasdaq exchange under the symbol EDIT, issued 5.9 million shares priced at $16.00. As of 12 noon on 3 February, the stock is…